US Senate panel to vote on RFK Jr.'s health secretary nomination
FILE PHOTO: Robert F. Kennedy Jr., U.S. President Trump’s nominee to be secretary of Health and Human Services, testifies before a Senate Health, Education, Labor, and Pensions (HELP) Committee confirmation hearing on Capitol Hill in Washington, U.S., J
(Reuters) - A U.S. Senate committee will vote Tuesday on whether to advance President Donald Trump's nomination of Robert F. Kennedy Jr. to lead the Department of Health and Human Services, the committee announced Sunday.
In contentious confirmation hearings before the Senate Finance Committee last week, Senate Democrats accused Kennedy of being financially vested in the anti-vaccine movement and peddling conspiracy theories to sow doubt about lifesaving medicines -- assertions Kennedy rejected.
If confirmed, Kennedy would run the U.S. Department of Health and Human Services, which oversees more than $3 trillion in healthcare spending, including agencies such as the Food and Drug Administration and the agency in charge of Medicare and Medicaid health insurance programs covering tens of millions of Americans.
A key committee member, Republican Bill Cassidy, added to doubts, saying he was "struggling" with Kennedy's nomination due to his positions on vaccines.
In a sign of the tensions within the Republican Party over the nomination, fellow Louisiana lawmaker Rep. Clay Higgins posted a photo of Cassidy to the social media site X, saying Kennedy would be confirmed with or without Cassidy's support: "Either way, we're watching."
(Reporting by Douglas Gillison; Editing by Aurora Ellis)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UK police arrest 5 by air base under terrorism act
- Bangkok floodwaters recede after torrential rain as residents count losses
- US 'very much' understands Taiwan's defence needs, Taipei official says
Create E-mail Alert Related Categories
ReutersRelated Entities
Donald J. Trump, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share